Vividion Therapeutics, Inc.

18 articles with Vividion Therapeutics, Inc.

• Vividion Brings in Proven Industry Leader Jeffrey Hatfield as Chief Executive Officer

  11/23/2020

  Vividion Therapeutics, a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer.

• Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

  5/19/2020

  Multi-Target Collaboration Leverages Vividion's Screening Platform to Discover and Develop Highly Selective Small Molecules for E3 Ligases and Select Oncology and Immunology Targets

• 

  Vividion and Roche Partner on Research Pact Worth "Several Billion Dollars"

  5/19/2020

  The companies will leverage Vividion’s proteomics screening platform and small molecule library to target novel E3 ligases in addition to a variety of oncology and immunology therapy targets.

• Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Annual Meeting

  5/15/2020

  First Reported E3 Ligase Beyond Cereblon and VHL Shown to Support Broad Targeted Protein Degradation of Multiple Targets In Vivo   [15-May-2020]   SAN DIEGO , May 15, 2020 /PRNewswire/ -- Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced data des

• 

  Beyond COVID-19: Biotech Beach Companies Reinvigorate Small Molecules, Cannabinoids and More

  4/15/2020

  The COVID-19 battle dominates the news, but it doesn’t constitute all the news. Here’s what several Southern California Biotech Beach companies are doing that you might have missed.

• Vividion Therapeutics Appoints Drug Discovery and Development Expert, Robert Abraham, Ph.D., as Chief Scientific Officer

  2/11/2020

  Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced the appointment of Robert Abraham, Ph.D., as Chief Scientific Officer

• Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing

  4/30/2019

  Bolsters capital to advance lead programs into the clinic and broaden early-stage pipeline of therapeutics against previously intractable drug targets

• 

  Vividion Secures $82 Million to Advance Its Lead Programs into the Clinic

  4/30/2019

  For Vividion, the financing round comes about a year after the company forged a $101 million collaboration with Celgene.
• 

  Highlight: A Dozen of the Forbes 30 Under 30 in Healthcare

  11/14/2018

  Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
• 

  Movers and Shakers Oct. 1

  10/1/2018

  Here's a look at who shook things up in the world of pharma and biotech this week.

• Vividion Therapeutics Expands Leadership Team with the Appointments of Fred Aslan, M.D., President and Chief Business Officer, and Larry Burgess, Ph.D., Head of Chemistry

  9/25/2018

  Vividion Therapeutics today announced the appointments of Fred Aslan, M.D. as President and Chief Business Officer and Larry Burgess, Ph.D. as Head of Chemistry.

• 

  Celgene Plans To File Second NDA for Ozanimod in 2019 Following FDA Rejection in February

  5/4/2018

  Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
• 

  Celgene’s COO Resigns as Company Shakes up Leadership Structure

  4/3/2018

  Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
• 

  Celgene Partners with Prothena Therapeutics in Potential $2B Deal

  3/21/2018

  Prothena Therapeutics has forged a collaboration with Celgene worth a potential $2B to develop new therapies for a broad range of neurodegenerative diseases.
• 

  Vividion Therapeutics Snags $101M from Celgene

  3/5/2018

  Celgene handed over $101 million in upfront monies to San Diego-based Vividion Therapeutics, Inc. as part of an agreement to develop small molecule therapies.

• Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets

  3/5/2018

  Vividion Therapeutics, Inc. announced a strategic research collaboration with Celgene Corporation.

• San Diego Biotech Startup Vividion Therapeutics Names A CEO

  9/7/2017

• Vividion Therapeutics Launches With $50 Million and a Celgene Alum as Executive Chairman

  2/2/2017